Summary & Overview
CPT 82668: Erythropoietin Level Assay
CPT code 82668 represents a quantitative laboratory assay for erythropoietin, a kidney-produced glycoprotein hormone that regulates red blood cell production. The test is clinically important for distinguishing primary polycythemia from secondary causes and for investigating unexplained anemia or impaired erythropoiesis. Nationally, erythropoietin measurement supports diagnostic pathways in hematology and nephrology and can influence downstream diagnostic imaging, referral, and management decisions.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical indications and typical sites of service, plus benchmarking context where available. The publication summarizes common billing considerations, payer coverage patterns, and how the assay fits into diagnostic algorithms for polycythemia and related disorders.
This report provides clinicians, billing professionals, and policy analysts with concise clinical context for CPT code 82668, an outline of what payers typically consider in coverage, and pointers to areas where policy updates or reimbursement clarifications are commonly sought. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 82668 measures the level of erythropoietin, a glycoprotein hormone primarily produced by the kidneys that regulates red blood cell production. This laboratory assay assists clinicians in differentiating primary versus secondary polycythemia and in evaluating conditions where erythropoiesis is impaired or dysregulated.
Service Type: Laboratory testing (quantitative hormone assay)
Typical Site of Service: Clinical laboratory or hospital laboratory
Clinical & Coding Specifications
Clinical Context
A 58-year-old male with chronic obstructive pulmonary disease and a hemoglobin level of 18.5 g/dL is referred to hematology to evaluate erythrocytosis. The clinician orders an erythropoietin level to help distinguish primary polycythemia (polycythemia vera) from secondary causes such as hypoxia-driven erythrocytosis or EPO-secreting tumors. Blood is drawn in the outpatient clinic, labeled, and sent to the hospital core laboratory. The laboratory performs quantitative immunoassay for erythropoietin and reports concentration with reference range. Results are reviewed by the ordering physician, who integrates the EPO level with complete blood count, oxygen saturation, and, if indicated, JAK2 mutation testing to determine diagnosis and next steps.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional Component | Use when only the physician interpretation/report of the lab result is billed separately from the technical service |
90 | Reference (Outside) Laboratory | Use when the test is performed by an outside independent laboratory and billed through the reporting facility |